Last reviewed 2026-04-22 · How we verify

CAIV-T, Liquid

CAIV-T is a live attenuated influenza vaccine administered as a nasal spray that stimulates mucosal and systemic immune responses against influenza.

CAIV-T is a live attenuated influenza vaccine administered as a nasal spray that stimulates mucosal and systemic immune responses against influenza. Used for Seasonal influenza prevention in children and adults.

At a glance

Mechanism of action

CAIV-T contains temperature-sensitive, attenuated influenza virus strains that replicate in the cooler upper respiratory tract but not in warmer lower respiratory tissues, triggering both local mucosal immunity and systemic antibody responses. The vaccine is designed to provide protection against seasonal influenza strains while minimizing systemic reactogenicity associated with inactivated vaccines.

Approved indications

• Seasonal influenza prevention in children and adults

Common side effects

• Nasal congestion
• Runny nose
• Sore throat
• Cough
• Fever

Key clinical trials

• Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T) (PHASE2)
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults (PHASE3)
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) (PHASE3)
• Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age (PHASE3)
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older (PHASE2)
• Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (PHASE3)
• A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. (PHASE2)
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.